Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR | Market Cap | 3.75B -36.8% |
| Revenue (ttm) | 1.72B -4.5% |
| Net Income | 77.66M +5.3% |
| EPS | 5.84 -4.0% |
| Shares Out | 12.71M |
| PE Ratio | 50.43 |
| Forward PE | n/a |
| Dividend | 1.00 (0.33%) |
| Ex-Dividend Date | Sep 19, 2025 |
| Volume | 1,203 |
| Average Volume | 1,182 |
| Open | 296.15 |
| Previous Close | 297.50 |
| Day's Range | 293.20 - 312.05 |
| 52-Week Range | 277.05 - 545.20 |
| Beta | 0.46 |
| RSI | 33.56 |
| Earnings Date | Feb 13, 2026 |
About Medicamen Biotech
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi,... [Read more]
Financial Performance
In fiscal year 2025, Medicamen Biotech's revenue was 1.68 billion, a decrease of -6.56% compared to the previous year's 1.79 billion. Earnings were 71.08 million, a decrease of -34.97%.
Financial StatementsNews
Medicamen Biotech secures USFDA nod for Bortezomib injection, marks its first ANDA approval
Medicamen Biotech Limited announced on June 3, 2025, that it has received its first Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Bortezomib f...
Medicamen Biotech shares surge 8% after signing contract for CDMO with XGX pharma
Medicamen Biotech Ltd saw its shares jump 8% after announcing a major contract development and manufacturing organization (CDMO) deal with XGX Pharma, a European pharmaceutical company. As part of thi...
Medicamen Biotech expands into South Africa after EU approval, eyes $4 billion pharmaceutical market
Medicamen Biotech Limited (MBL) has announced a strategic move to expand its presence in the South African pharmaceutical market. The company has entered into an agreement with a prominent South Afric...
Medicamen Biotech shares jump 3.50% after signing long-term manufacturing deal for US and Europe
Shares of Medicamen Biotech Ltd. surged 3.55% to ₹514.45 in early trade on February 20 after the company announced a significant Manufacturing & Supply Agreement with a leading pharmaceutical distribu...
Medicamen Biotech secures 10-year manufacturing and supply deal with leading US pharma distributor
Medicamen Biotech Limited has entered into a long-term Manufacturing & Supply Agreement with a prominent pharmaceutical distributor and marketing company operating in the US and European markets. The ...
Medicamen Biotech shares surge nearly 15%
Shares of Medicamen Biotech soared by 14.06% as of 9:39 AM, trading at ₹492.05, following the company’s announcement of securing a ₹6.28 crore order for the supply of Povidone Iodine Solution. Key Hig...